Clinical studies have demonstrated that fulvestrant is effective in slowing the progression of hormone receptor-positive metastatic breast cancer. In comparative trials, fulvestrant has shown to be at least as effective as other endocrine therapies and, in some cases, superior in extending progression-free survival. However, the effectiveness can vary depending on individual patient factors and prior treatments.
